Eli Lilly has agreed to buy a gene-editing program for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biotech’s recent restructuring drive.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,